Gain Therapeutics (GANX)
(Delayed Data from NSDQ)
$1.58 USD
-0.12 (-7.06%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $1.60 +0.02 (1.27%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Gain Therapeutics, Inc. has a market cap of $61.11M, which represents its share price of $1.70 multiplied by its outstanding shares number of 35.95M. As a small-cap company, GANX's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
GANX 1.58 -0.12(-7.06%)
Will GANX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for GANX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GANX
All You Need to Know About Gain Therapeutics (GANX) Rating Upgrade to Strong Buy
Best Momentum Stocks to Buy for January 9th
GANX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for GANX
GANX Fell Below 50 Day Moving Average on September 19
GANX Crossed Above 50 Day Moving Average on September 19
GANX forms Directional Movement Crossover Bearish on September 17
Gain Therapeutics (GANX) Extends Phase 1b Study for Parkinson's Treatment
Gain Therapeutics begins GT-02287 Phase 1b extension study in Parkinson’s